Morgan Stanley analyst Emmet Kelly resumed coverage of Cellnex with an Equal Weight rating and EUR 44 price target. The company’s organic growth story is underappreciated, but its step back from expansionary acquisitions removes an opportunity to "turbo-charge" its bottom line, Kelly tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly